Tesamorelin
GHRH analog for visceral fat.
Mechanism of Action
Increases natural GH.
Key Benefits
- Reduces visceral belly fat
Common Uses
What to Expect
Onset
Visceral fat reduction noticeable at 2–4 weeks; cognitive benefits may take 4–8 weeks
Duration
Effects accumulate over months of continuous use; visceral fat loss is progressive
What Users Report
- Noticeable reduction in deep belly fat — waist measurements decrease even when scale weight is stable
- The fat loss feels different from dieting — it targets the hard, visceral fat around organs, not just subcutaneous
- Some users report improved mental clarity and cognitive sharpness, consistent with clinical data
- Better sleep quality from the GH-releasing mechanism
- Mild joint stiffness or achiness initially, which typically resolves within the first few weeks
- Improved body composition metrics (DEXA scans show visceral fat reduction) even without dramatic scale changes
- A general sense of improved metabolic health — blood panels often improve alongside the fat loss
Typical Timeline
Weeks 1–2: Sleep improvement; possible mild joint stiffness. Weeks 2–4: Waist measurements begin decreasing; belt notches tighten. Weeks 4–8: Visible visceral fat reduction; cognitive improvements emerge. Months 2–6+: Progressive improvement in body composition and metabolic markers.
Side Effects
- Mild joint pain possible
Dosage Protocol
1–2 mg subcutaneously nightly. Cycles: Continuous for approved uses; monitor IGF-1.
Always consult a physician before starting any peptide protocol.
Administration
Injection
FDA Status
FDA-approved for specific use
Stacks Well With
- AOD 9604
Tags
Related peptides
AOD 9604
HGH Fragment 177-191 analog
Fat-burning fragment of HGH.
CJC-1295 (with/without DAC)
Growth Hormone Releasing Hormone analog
Long-acting GH secretagogue.
Ipamorelin
Selective ghrelin mimetic – safest GH peptide.
Semaglutide
GLP-1 agonist
FDA-approved weight-loss powerhouse.